4DMedical (ASX:4DX) lands TGA approval and Australia’s 74-scanner-per-million density now goes to work

Home market clearance opens an MSAC reimbursement pathway and gives CT VQ a sixth regulatory tick

4DMedical (ASX:4DX) has secured TGA approval for its CT VQ software in Australia, adding the home market to a regulatory list that already includes the US, EU, UK, Canada and New Zealand. It is the sixth jurisdiction to clear the product, and the one with arguably the most favourable infrastructure backdrop in the world.

Australia carries the second-highest CT scanner density on the planet at more than 74 machines per million people. That matters because CT VQ is a software-only, non-contrast functional lung imaging tool that runs on scanners hospitals already own. There is no capital sale, no contrast agent, no nuclear medicine suite required.

The bigger news sitting underneath the approval is the MSAC submission now in preparation. Without Medicare Benefits Schedule reimbursement, Australian adoption stays bounded by what hospitals will fund themselves. With it, CT VQ becomes a billable line item across the country’s radiology workflow.

For a stock that has spent the past 18 months building international validation through Mayo, Stanford, Cleveland Clinic and SimonMed, the home market finally joining the party is overdue. The question now is how fast a software-only product can convert a favourable infrastructure base into actual revenue.

Why Australia is a better launch market than the headline suggests

The scanner density number is the obvious hook, but the real edge sits in regional and rural Australia. Nuclear medicine services in those markets are patchy at best, with many smaller hospitals running CT but no radiotracer infrastructure. CT VQ walks straight into that gap.

That distribution advantage matters because traditional VQ scanning in Australia is concentrated in a handful of metropolitan centres. A software product that lets a regional hospital deliver functional lung assessment using its existing CT scanner expands the addressable patient pool without expanding the cost base.

We think this is the most underappreciated piece of the announcement. The Australian healthcare system actively rewards solutions that decentralise specialist diagnostics, and CT VQ is exactly that profile.

The MSAC pathway is the real catalyst, not the approval itself

TGA approval is necessary but not sufficient. The Medical Services Advisory Committee submission is what determines whether CT VQ generates meaningful Australian revenue or sits on the shelf waiting for hospitals to find budget.

MSAC reviews are notoriously slow. Even a clean submission with strong clinical evidence and health-economic modelling typically takes 12 to 24 months to translate into an MBS item number. Investors should not expect Australian reimbursement revenue inside FY26.

The skeptical read is that 4DMedical has cleared the easier hurdle and the harder one is still in front of it. The constructive read is that the international evidence base, particularly the US deployments, gives this submission a stronger foundation than most early-stage MSAC applications.

Where TGA approval sits in the global story

Six markets cleared is a credibility signal that the company can now use in every reimbursement conversation worldwide. Regulators talk to each other, and a product approved across the US, EU, UK, Canada, New Zealand and now Australia carries different weight in negotiations than a product approved in one or two.

The SimonMed agreement announced earlier in the US showed CT VQ working in high-volume community radiology, not just academic medical centres. That same template applies in Australia, where private outpatient imaging chains handle a large share of national CT volume.

Our view is that the Australian rollout will look more like SimonMed than Stanford. Volume players adopting a software upgrade across existing networks will move faster than teaching hospitals committing to new clinical workflows.

The Investors Takeaway for 4DMedical

TGA approval is a clean tick in the box and a credibility boost for the broader global expansion story, but the real Australian revenue story lives or dies on MSAC. Without MBS reimbursement, this becomes a slow hospital-by-hospital sales grind in a market where 4DMedical already has strong clinician relationships but limited budget unlock.

Investors should also keep watching the US momentum, which remains the bigger near-term contributor. Mayo Clinic evaluation progressing to a commercial deployment would do more for the share price than any single international approval. Readers can find our previous coverage of the CLEAR trial and the broader CT VQ thesis at stocksdownunder.

2026 was always going to be the year 4DMedical needed to convert regulatory wins into recurring SaaS revenue. The Australian approval is one more brick in that wall. The MSAC submission is the one to watch.